Mytigate, a firm established in Eschborn, Germany, began its operations in 2020. It is a digital platform that helps pharmaceutical companies and their forwarders to conduct pharma lane risk assessments in order to ensure compliance with good distribution practice (GDP) regulations and to improve the quality of pharma transport.
Mytigate operationalizes the results of the “Pharma Supply Chain Risk Management” research project, which was initiated by Frankfurt University together with Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG and the forwarder GEFCO Forwarding Germany GmbH. The project was funded by the LOEWE3 innovation fund of the state of Hesse that supports outstanding joint scientific projects between universities and private firms. The company’s primary goal is to assess pharma lane risks, through ensuring compliance with good distribution practice (GDP) rules , to reduce the impact of pharma transport incidents. It is a digital platform that helps pharmaceutical businesses, forwarders, and supply-chain partners comply with regulations.
Prof. Dr. Yvonne Ziegler, CEO